Data from the study presented here suggest that in addition to targeting the PI3K/AKT/mTOR pathway in ERMS, additional combinational targeting of AMPK and STAT signaling with specific small molecule inhibitors, or more efficacious curcumin derivatives in development [51], may offer significant promise in treating this aggressive pathology. The gene discussed is PRKAA2; the disease is embryonal rhabdomyosarcoma.